Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Melanoma (Skin) Clinical Trial

Official title:

A Phase II Placebo-controlled Intervention Trial of Oral Aspirin (ASA) as a UV Protectant in Vivo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04066725
• Other study ID #: HCI94424
• Status: Completed
• Phase: Phase 2
• Start date: July 25, 2019
• Est. completion date: March 19, 2021

Study information

• Verified date: February 2022
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.

Description:

While melanoma risk is largely genetically determined, exposure to ultraviolet (UV) radiation in sunlight is the major environmental risk factor. Although sunscreen use can reduce melanoma risk 2-fold, its efficacy has been questioned, and most patients do not apply sunscreens properly. This study will evaluate the downstream effects of aspirin (ASA) in human blood and skin moles (nevi) following oral ingestion. We will determine if chronic ingestion of ASA can modulate UV-sensitivity of the skin, UV-induced damage in nevi, and PGE2 levels in blood and nevi.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: March 19, 2021
• Est. primary completion date: March 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have at least 2 nevi (each >5 mm diameter) not clinically suspicious for melanoma that can be biopsied.
• Must be older than age 18.
• Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• The patient cannot speak / understand English or Spanish.
• The patient is pregnant or breastfeeding.
• The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.
• The patient has history of allergic reaction to ASA.
• The patient has history of severe asthma.
• The patient has been taking ASA or any NSAID in the past 2 weeks.
• The patient has been taking a blood thinner in the past 2 weeks.
• The patient has history of bleeding disorder.
• The patient has history of peptic ulcer disease.
• The patient has had recent intense UV exposure in the past month.

Related Conditions & MeSH terms

• Melanoma
• Melanoma (Skin)

Intervention

Drug:
• Aspirin 81 mg
Participants will be given ASA 81 mg orally once daily for a total of 60 days
• Aspirin 325mg
Participants will be given ASA 325 mg orally once daily for a total of 60 days
• Placebo oral tablet
Participants will be given placebo orally once daily for a total of 60 days

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in minimal erythemal dose (MED) from baseline to day 60.	Baseline minimal erythemal dose (MED) measurements will will be compared to MED results at day 60. We will use the conventional definition of MED as the lowest UV dose resulting in erythema that completely fills the 8-mm irradiated site (homogeneous erythema).	Change from baseline to day 60
Primary	Change in concentration of prostaglandin E2 (PGE2) in plasma from baseline to day 60.	Baseline PGE2 levels in plasma specimens will be compared to PGE2 levels at day 60.	Change from baseline to day 60
Primary	Change in concentration of prostaglandin E2 (PGE2) in nevus tissue from baseline to day 60.	Baseline PGE2 levels in tissue specimens will be compared to PGE2 levels at day 60.	Change from baseline to day 60
Secondary	Change in concentration of oncometabolite 2-hydroxyglutarate (2-HG) in plasma from baseline to day 60.	Baseline 2-HG levels in plasma specimens will be compared to 2-HG levels at day 60.	Change from baseline to day 60
Secondary	Change in concentration of 8-oxoguanine (8-OG) in plasma from baseline to day 60.	Baseline 8-OG levels in plasma specimens will be compared to 8-OG levels at day 60.	Change from baseline to day 60
Secondary	Change in concentration of oncometabolite 2-hydroxyglutarate (2-HG) in nevus tissue from baseline to day 60.	Baseline 2-HG levels in tissue specimens will be compared to 2-HG levels at day 60.	Change from baseline to day 60
Secondary	Change in concentration of 8-oxoguanine (8-OG) in nevus tissue from baseline to day 60.	Baseline 8-OG levels in tissue specimens will be compared to 8-OG levels at day 60.	Change from baseline to day 60